Taylor & Francis Group
lmsa_a_2216757_sm7568.docx (2.65 MB)

Dual-responsive targeted hollow mesoporous silica nanoparticles for cancer photodynamic therapy and chemotherapy

Download (2.65 MB)
journal contribution
posted on 2023-05-26, 12:20 authored by Yuqi Chen, Xuelian Wang, Zhuhang Lu, Cong Chang, Yueli Zhang, Bo Lu

Surface modification of hollow mesoporous silica nanoparticles (HMSNs) with unique advantages are highly promising for drug delivery and have emerged for effective cancer treatment. In this study, functionalized nanoparticles for targeting and dual-responsive release of loaded doxorubicin hydrochloride (DOX·HCL) and indocyanine green (ICG) (labeled as ID@HCH). In addition, chitosan (CS) was conjugated onto the HMSNs as capping agents and then dialdehyde hyaluronic acid (HDA) was modified to endow the ability to target the CD44 receptor. The characterizations demonstrated that nanocarriers have been successfully constructed with excellent drug loading capacity (DL) and drug entrapment efficiency (EE). The in vitro DOX control release displayed pH/enzyme-response properties owing to the pH-dependent swelling effect of chitosan and the HDA degraded by hyaluronidases (HAase). Moreover, the results of in vitro cell experiments proved that the ID@HCH could inhibit the cancer cells viability via accurately targeting HepG2 cells and chemotherapy combined with photodynamic therapy. This study demonstrated that ID@HCH is a new promising dual-responsive drug delivery system for chemotherapy and photodynamic therapy.


This work was financially supported by the National Natural Science Foundation of China (grant number 51773162 and 21204071), the Key Project in Science Research Program from Education Department of Hubei (grant number D20182004).